In recent years, agents inhibiting angiopoietin-like protein 3 (ANGPTL3) have been developed and have been shown to be effective in a wide spectrum of lipid disorders, including homozygous hypercholesterolemia1–3, refractory hypercholesterolemia4, mixed hyperlipidemia5 and severe hypertriglyceridemia with chylomicronemia provided that lipoprotein lipase (LPL) is bioavailable6. Here, ANGPTL3 is linked to hypertriglyceridemia.